Study: Infliximab may be better than adalimumab for UC remission

10/16/2013 | MedPage Today (free registration)

A Canadian meta-analysis presented at the ACG Annual Scientific Meeting suggests infliximab may be more effective at inducing remission than adalimumab for patients with ulcerative colitis. Both anti-tumor necrosis factor drugs are FDA-approved for treating ulcerative colitis in patients who do not respond to or tolerate conventional therapy.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL